Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Information is limited or lacking on fidaxomicin treatment of Clostridium difficile infection (CDI) in patients with inflammatory bowel disease, fulminant or life-threatening CDI, severe renal impairment, moderate-to-severe hepatic impairment and pregnancy. The ANEMONE study investigated fidaxomicin...

Descripción completa

Detalles Bibliográficos
Autores principales: Vehreschild, Maria J. G. T., Taori, Surabhi, Goldenberg, Simon D., Thalhammer, Florian, Bouza, Emilio, van Oene, Joop, Wetherill, Graham, Georgopali, Areti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315004/
https://www.ncbi.nlm.nih.gov/pubmed/30099637
http://dx.doi.org/10.1007/s10096-018-3344-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315004/
https://www.ncbi.nlm.nih.gov/pubmed/30099637
http://dx.doi.org/10.1007/s10096-018-3344-1

Ejemplares similares